Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran

Area of Science:

• Biochemistry and Molecular Biology
• Cardiovascular Medicine
• Pharmacology

Background:

• Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for preventing atherosclerotic cardiovascular disease (ASCVD).
• Existing non-statin therapies for LDL-C reduction are underutilized due to various barriers, leaving many patients below guideline-recommended goals.
• Increasing ASCVD mortality necessitates novel therapeutic strategies for effective LDL-C lowering.

Purpose of the Study:

• To review the development of inclisiran, a novel RNA interference therapeutic targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
• To discuss the clinical trial program, characteristics, and practical application of inclisiran for LDL-C reduction.
• To highlight inclisiran's journey from discovery to its approval as a treatment for hyperlipidemia and ASCVD prevention.

Main Methods:

• Inclisiran utilizes RNA interference to inhibit hepatic PCSK9 synthesis, a key regulator of LDL receptors.
• The therapeutic regimen involves initial loading doses followed by maintenance subcutaneous injections twice yearly.
• Clinical trials assessed the efficacy, safety, and tolerability of inclisiran, particularly when added to maximally tolerated statin therapy.

Main Results:

• Inclisiran demonstrated a sustained reduction in circulating LDL-C levels by approximately 50% compared to placebo.
• The twice-yearly dosing regimen proved effective in significantly lowering LDL-C in patients with established ASCVD or familial hypercholesterolemia.
• Long-term safety and tolerability data are being collected, with ongoing studies evaluating cardiovascular outcomes.

Conclusions:

• Inclisiran represents a significant advancement in LDL-C lowering therapy, offering a novel mechanism of action via RNA interference.
• Its convenient dosing schedule addresses adherence challenges associated with previous non-statin therapies.
• Inclisiran provides a valuable new option for managing hyperlipidemia and preventing atherosclerotic cardiovascular disease.